CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.14, sa.6, ss.525-533, 2014 (SCI-Expanded)
The aim of this study was to investigate the presence of Janus kinase 2 (JAK2) V617F mutation in patients with BCR-ABL negative chronic myeloproliferative neoplasms (CMPNs) in our center. JAK2 V617F mutation frequencies in our PV and ET patients were similar to those reported previously. JAK2 V617F mutation frequency in our PMF patients was greater than in previous reports.